ERBB2 and breast cancer: in 168 patients, SUV values in PET/CT scans obtained before neoadjuvant treatment correlated with molecular breast cancer subtype, with significantly higher SUV measures seen in HER2-positive tumors and in the basal-like subtype, which is mostly comprised of TNBC (72).